Browsing ICR Divisions by author "Alataki, Anastasia"
Now showing items 1-4 of 4
-
A simple digital image analysis system for automated Ki67 assessment in primary breast cancer.
Alataki, A; Zabaglo, L; Tovey, H; Dodson, A; Dowsett, M (WILEY, 2021-08-01)AIMS: Ki67 is a well-established immunohistochemical marker associated with cell proliferation that has prognostic and predictive value in breast cancer. Quantitative evaluation of Ki67 is traditionally performed by assessing ... -
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino, MA; López-Knowles, E; Morani, G; Tovey, H; Kilburn, L; et al. (ELSEVIER, 2022-08-16)BACKGROUND: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the ... -
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer.
Alataki, A; Dowsett, M (BIOSCIENTIFICA LTD, 2022-08-01)Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the ... -
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
Haynes, BP; Schuster, G; Buus, R; Alataki, A; Ginsburg, O; et al. (SPRINGER, 2021-11-01)PURPOSE: Changes occur in the expression of oestrogen-regulated and proliferation-associated genes in oestrogen receptor (ER)-positive breast tumours during the menstrual cycle. We investigated if Oncotype® DX recurrence ...